1 st Department of Anesthesia and Intensive Care, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj- Napoca; Research Association in Anesthesia and Intensive Care (ACATI), Cluj-Napoca; Department of Anesthesia and Intensive Care, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Cluj-Napoca, Romania.
Department of Surgery, Iuliu Haţieganu University of Medicine and Pharmacy Cluj- Napoca, Romania.
J Gastrointestin Liver Dis. 2023 Jun 22;32(2):156-161. doi: 10.15403/jgld-4962.
In the last years increasing scientific evidence drew attention on the potential effects of anesthetic drugs on postoperative outcome in cancer patients. Local anesthetics, especially lidocaine, have been intensively studied in relation with postoperative outcome in colorectal cancer patients. Our study objectives were to investigate the effects of perioperative intravenous lidocaine infusion on neutrophil-to-lymphocyte ratio and short-term postoperative outcome. Additionally, we also looked at 1 year outcome after intended radical colorectal cancer surgery.
150 patients scheduled for colorectal cancer surgery were randomized to receive sevoflurane anaesthesia with or without 48 hours lidocaine infusion.
73 patients were included in the group A (sevoflurane) and 77 in the group B (sevoflurane with lidocaine). Lidocaine infusion did not modify neutrophil-to-lymphocyte ratio at 24 hours after surgery (p=0.58). Patients receiving intravenous lidocaine had significantly lower morphine consumption (p=0.04), faster mobilization time (p=0.001) and fewer days spent in the hospital (p=0.04). Moreover, at 1 year follow- up, patients in group B had a significant decreased rate of recurrences (p=0.03). There was no significant difference in 1 year survival (p=0.22).
In our study, intravenous lidocaine infusion hastened the postoperative recovery of patients in terms of mobilization, hospital discharge and opioid consumption and reduced 1 year recurrence rate. Further studies on larger groups of patients are needed.
近年来,越来越多的科学证据引起了人们对麻醉药物对癌症患者术后转归影响的关注。局部麻醉药,特别是利多卡因,在结直肠癌患者的术后转归方面已经得到了广泛研究。我们的研究目的是探讨围手术期静脉输注利多卡因对中性粒细胞与淋巴细胞比值(NLR)和短期术后转归的影响。此外,我们还观察了计划行根治性结直肠癌手术后 1 年的转归。
将 150 例拟行结直肠癌手术的患者随机分为接受七氟醚麻醉(A 组)或七氟醚麻醉加 48 小时利多卡因输注(B 组)。
A 组(七氟醚)和 B 组(七氟醚加利多卡因)分别纳入 73 例和 77 例患者。输注利多卡因并不改变术后 24 小时的 NLR(p=0.58)。接受静脉内利多卡因输注的患者吗啡消耗量显著减少(p=0.04),下床活动时间更早(p=0.001),住院天数更少(p=0.04)。此外,在 1 年随访时,B 组患者的复发率显著降低(p=0.03)。1 年生存率无显著差异(p=0.22)。
在我们的研究中,静脉内输注利多卡因可加速患者术后恢复,缩短下床活动时间、出院时间和阿片类药物使用时间,并降低 1 年复发率。需要对更大的患者群体进行进一步研究。